Find Academic Supervisors

• Cancer epidemiology
• Ovarian cancer
• Endometrial cancer
• +5 more

Professor Susan Jordan is a medically trained cancer epidemiologist and NHMRC Leadership Fellow at the University of Queensland's School of Public Health. She specializes in ovarian, endometrial, and thyroid cancer research, focusing on aetiology, patterns of care, and survival outcomes. Her work combines large-scale data linkage, molecular epidemiology, and clinical surveys. She leads projects addressing disparities in cancer care and has contributed to revised chemotherapy guidelines and highlighted rural-urban survival gaps. Education: Bachelor (Honours) of Medicine and Surgery and Medical Science, University of New South Wales Graduate Diploma in Clinical Epidemiology, University of Newcastle Doctor of Philosophy, The University of Queensland Research Interests: Investigating reproductive factors in cancer development (e.g., breastfeeding, hormonal influences) Modifiable risk factors for ovarian, endometrial, and thyroid cancers Impact of clinical practices (e.g., hysterectomy, oophorectomy) on long-term health outcomes Disparities in cancer survival and treatment access Recent Article Trends: Her research emphasizes translational epidemiology, linking population-level data to clinical practice. Recent work focuses on contraceptive use, hormone therapy effects, and disparities in screening participation among vulnerable populations. Studies highlight the need for evidence-based guidelines to improve long-term outcomes for surgical interventions. Scientific Awards and Contributions: Pioneered studies on fallopian tube origins of ovarian cancer Contributed to updated ovarian chemotherapy protocols Highlighted rural-urban cancer survival disparities Supervision and Grants: Current projects include the HOLD study on hysterectomy long-term effects Supervised over 15 PhD students focusing on cancer epidemiology and public health Funded by NHMRC, HCF, and Cancer Australia for projects on cancer prevention and survivorship Labs and Collaborations: Affiliated with the Australian Women's and Girls' Health Research Centre, collaborating on large consortia (e.g., Ovarian Cancer Association Consortium). Active in interdisciplinary teams addressing cancer epidemiology and health equity.

Hossam AbdelsamedView profile

Assistant Professor

• Immunology
• T Cell Biology
• Autoimmunity
• +3 more

Dr. Hossam Abdelsamed is an Assistant Professor of Physiology at the Medical College of Georgia, specializing in cellular and molecular immunology with a focus on T cell biology and autoimmune mechanisms. His work examines self-reactive T cells in chronic inflammatory diseases like atherosclerosis, employing human PBMCs, mouse models, and organoid systems. Education: PhD in Biomedical Sciences from the University of Tennessee Health Science Center (2012), and a BS in Biochemistry from Ain Shams University (2001). Teaching: Courses include MOIM 9210 (Investigation of a Problem), BIOM 8230 (Biology of Proteins in Disease), and CURS 4990 (Undergraduate Research III). Teaching emphases include innate immunity, T cell biology, and tolerance/autoimmunity. Research Trends: Recent studies explore bystander T cell activation, epigenetic regulation in immune cells, and cytokine roles in viral infections. His work highlights cross-talk between T cell subsets and their implications in autoimmune and chronic inflammatory conditions. Advising & Grants: No formal advisee list is provided, but his research activities suggest involvement in grant-funded projects related to T cell biology and immunotherapeutic targets. No specific grants mentioned.

Ismail AkturkView profile

Adjunct Assistant Professor

• Neuromorphic Computing
• Hardware Security
• Heterogeneous Systems
• +5 more

Ismail Akturk serves as an Adjunct Assistant Professor in the Electrical Engineering and Computer Science (EECS) department with a courtesy appointment. His research bridges hardware architecture, neuromorphic computing, and security, focusing on energy-efficient systems and novel computational paradigms. His research interests center on neuromorphic engineering with significant contributions to Intel's Loihi architecture, implementing bio-realistic neural models and exploring scaling limits. He investigates hardware security through microarchitectural vulnerability assessments and develops frameworks for secure edge computing. His work in heterogeneous systems includes optimizing parallel programming models across GPUs and CPUs while pioneering techniques like weight update skipping and value recomputation to accelerate deep learning. Recent publications demonstrate a strong trajectory toward secure, energy-efficient neuromorphic systems with practical applications in edge environments. Dr. Akturk's publication record reveals a strategic evolution from distributed storage systems (2009-2012) toward cutting-edge neuromorphic and security research. His 2023-2025 work shows increasing focus on secure miniservers, RTL code generation via LLMs, and bio-realistic neural implementations – indicating convergence of AI, hardware security, and neuromorphic computing. The consistent emphasis on energy efficiency across publications suggests this remains a core research thread. His scientific contributions include novel frameworks like ACR (Amnesic Checkpointing and Recovery) and Holistic Hardware Security Assessment, though formal awards aren't documented in available sources. His methodology consistently combines theoretical modeling with hardware implementation, particularly evident in Loihi processor optimizations. As an adjunct faculty member, Dr. Akturk contributes to EECS education while maintaining active research output. His current trajectory suggests growing involvement in secure edge computing systems and neuromorphic AI acceleration, with potential implications for low-power IoT security and real-time neural processing applications.

Allison A. AkaView profile

Assistant Professor

• Colorectal Surgery
• Surgical Oncology
• Gastrointestinal Diseases
• +4 more

Allison A. Aka, MD, FACS, FASCRS is an Assistant Professor in the Department of Surgery, Colorectal Division at Loma Linda University School of Medicine. She holds a medical degree from Loma Linda University (2013). Her research focuses on colorectal surgery, surgical oncology, and innovative surgical techniques. Key interests include anastomotic complications, endoscopic interventions, and immunotherapeutic approaches to colorectal cancer. Her work spans 13 peer-reviewed publications since 2009, with recent emphasis on endoscopic stent applications, anorectal malignancies, and pediatric surgical outcomes. Notable contributions include studies on transanal mesorectal excision complications and guanylyl cyclase C as a therapeutic target. Education: MD from Loma Linda University (2013) Research Trends: Surgical innovation, cancer immunotherapy, and rare tumor management Professional Honors: Fellowships in American College of Surgeons (FACS) and American Society of Colon and Rectal Surgeons (FASCRS)

Jane Carr-WilkinsonView profile

Senior Lecturer

• Neuroblastoma research
• Stem cell differentiation
• Childhood cancer genomics
• +5 more

Jane Carr-Wilkinson is a Senior Lecturer in Pathology at the University of Sunderland's School of Medicine, specializing in neuroblastoma research and stem cell modeling. She leads phase one MBChB Medicine curriculum components in physiology and pathophysiology while contributing to international collaborative teaching initiatives as PVC Learning and Teaching Fellow in Transnational Education. Her research program investigates neuroblastoma pathogenesis through human pluripotent stem cell differentiation to neural crest cells, focusing on the molecular interplay between development and cancer initiation. She explores stemness genes, LGR5/WNT signaling pathways, and clonal evolution mechanisms in drug resistance. Article analysis reveals 15 years of publication activity (2003-2022) centered on neuroblastoma genetics (p53 pathway, MYCN), stem cell modeling, and drug resistance mechanisms. Collaborations with Newcastle University feature prominently, particularly in neurotoxicity studies of IPSC-derived neurons. Scientific awards include Senior Fellow of the Higher Education Academy. She co-investigates neurotoxicity mechanisms with Newcastle University and engages in Cancer Research UK's Race for Life initiatives.

• Organization Studies
• Human Resource Management
• Health Management
• +6 more

Prof. Rocco Reina is a Full Professor of Organization Studies & Human Resource Management at the Magna Graecia University of Catanzaro (UMG). He holds leadership roles including Director of the Bachelor Degree Course in 'Organization of Public and Private Administrations' and coordinates research on organizational models in healthcare and public administration. His work focuses on organizational change, healthcare management, and performance evaluation. Prof. Reina has extensive experience in academic administration, research projects, and consulting across public and private sectors. Education: PhD in Organization Technology and Human Resource Management (2000) from University of Molise, with advanced specialization in Business Administration and Economics. His teaching spans courses like Business Organization, Conflict Management, and Health Organization Studies. Research emphasizes healthcare organizational dynamics, intellectual capital, and pandemic response strategies. He publishes in journals like Journal of Intellectual Capital and collaborates with international organizations. Key contributions include analyzing organizational responses to the COVID-19 pandemic in Southern Italy and evaluating biologic therapies in inflammatory bowel diseases.

• Oncology
• Molecular Biology
• Cancer Immunotherapy
• +3 more

Katia Reda serves as a Contract Professor at the Department of Law, Economics and Sociology (DiGES) of the Università della Calabria (UniCZ). Her research focuses on innovative cancer therapies, particularly targeting hematologic malignancies and solid tumors through molecular mechanisms involving non-coding RNAs, immunotherapy, and targeted drug delivery systems. She has pioneered studies on bispecific T-cell engagers, G-quadruplex stabilization, and CRISPR-based approaches to identify novel therapeutic targets. Her work integrates bioinformatics, preclinical models, and clinical trial analysis to advance precision oncology. Key contributions include identifying MALAT1 triplex inhibitors and exploiting the cGAS/STING pathway in immunogenic cell death mechanisms. Katia's interdisciplinary approach bridges molecular biology, pharmacology, and immunology to address challenges in cancer treatment efficacy and resistance. Notably, her research has explored the role of miR-221/222 in cancer progression and the application of resveratrol in epigenetic modulation. She has also contributed to understanding genetic anomalies in rare cases of SRY-positive females through non-invasive prenatal testing insights. Despite her affiliation with the DiGES department, her research activities are primarily aligned with medical and life sciences disciplines, reflecting a transdisciplinary academic profile.

Aditi MulgaonkarView profile

Lecturer

• Molecular Imaging
• Nanomedicine
• Cancer Detection
• +4 more

Aditi Mulgaonkar, Ph.D., is an Instructor in the Department of Radiology at UT Southwestern Medical Center, affiliated with its Radiology Research Division. She previously served as a senior research associate in the Cyclotron and Radiochemistry Program, supporting Dr. Xiankai Sun's work on theranostic macromolecules. Her research focuses on radiotherapeutic nanoseeds, cancer theranostics, and antibody-based tumor detection using PET imaging, resulting in 14 peer-reviewed publications. Dr. Mulgaonkar holds a pharmacy degree from the University of Mumbai, a Ph.D. in pharmaceutical sciences from Virginia Commonwealth University, and postdoctoral training at the FDA and UT Southwestern. Her research interests emphasize molecular imaging advancements, particularly in bacterial infections and cancer diagnostics. She is a member of the Society of Nuclear Medicine and Molecular Imaging and contributes to editorial roles in journals like EC Pharmaceutical Science and International Journal of Nanomedicine. Her work spans drug transport studies, nanocrystal synthesis, and imaging techniques for CAR T-cell therapy. Ongoing projects include developing novel HIF2a PET tracers and refining immunoPET imaging for PD-L1 expression in renal cell carcinoma models. Her contributions bridge clinical translation and precision medicine, with a focus on nanotheranostics and radiolabeling strategies.

Lois WoodsView profile

Researcher

• Evidence Synthesis
• Systematic Reviews
• Healthcare Information Science
• +3 more

Lois Woods is a Senior Research Assistant at the University of Southampton, affiliated with the Southampton Health Technology Assessments Centre (SHTAC). She specializes in information science and evidence synthesis, contributing to systematic reviews and clinical trial methodologies. Her role involves designing search strategies, critical appraisal of evidence submissions for NICE, and supporting projects like the StOP UTI initiative to prevent urinary tract infections in care homes. She holds a postgraduate degree in Information Science and previously worked at Public Health England as a librarian. Lois actively participates in Cochrane Crowd and collaborates on interdisciplinary projects, including EU-funded research on immunomodulatory therapies for drug-resistant pneumonia. Her work spans healthcare resources, public health, and life sciences, emphasizing evidence-based practices. She also co-chairs the InterTASC ISSG and contributes to teaching systematic review methodologies. Her research interests include digital tools for clinical trial recruitment, healthcare resource optimization, and translational research. Lois has co-authored numerous publications on topics ranging from prostate cancer diagnostics to gene therapy, reflecting her expertise in evidence synthesis and health technology assessment.

Kevin AngstadtView profile

Assistant Professor

• Computer Architecture
• Programming Languages
• Software Engineering
• +3 more

Kevin Angstadt is an Assistant Professor of Computer Science at St. Lawrence University, part of the Department of Mathematics, Computer Science, and Statistics. He holds a Ph.D. from the University of Michigan (2020) and an MCS from the University of Virginia (2016), with undergraduate degrees in Computer Science, Mathematics, and German Studies from St. Lawrence University (2014). His research focuses on the intersection of computer architecture, programming languages, and software engineering, with an emphasis on optimizing programming support for emerging hardware technologies like accelerators and autonomous systems. Education: Ph.D. in Computer Science and Engineering, University of Michigan (2020) M.S. in Computer Science, University of Virginia (2016) B.S. in Computer Science, Mathematics, and German Studies, St. Lawrence University (2014) Research Interests: His work spans programming abstractions for hardware accelerators, fault-tolerant autonomous systems, and tools like MNRL and MNCaRT for automata processing. He also collaborates on projects such as StatKey, a statistical simulation tool used by over one million users. Recent Articles Trends: His publications emphasize hardware-software co-design, resilience in autonomous systems, and debugging support for pattern-matching languages. Recent work includes NSF-funded research on program repair and optimization, and frameworks like LOGI and START for secure autonomous vehicle operation. Awards: NSF Medium Grant ($1.2M, 2022) UVA Teaching and Service Award (2017) Jefferson Scholars Foundation Fellow (2014–2017) Best in Session Award at TECHCON 2016 Advising & Grants: He leads a $1.2M NSF grant and has advised projects on pattern-matching accelerators, autonomous vehicle resilience, and compiler optimization. Collaborates with industry and academic partners on mission-critical systems and software reliability. Labs/Teams: Core contributor to MNRL (automata processing ecosystem), StatKey (statistical tools), and the START project for resilient autonomous systems. Active in open-source development and hardware-accelerator research groups.

• Macromolecular Chemistry
• Drug Delivery Systems
• Nanogels
• +7 more

Professor Lutz Nuhn is Chair of Macromolecular Chemistry at the Julius Maximilian University Würzburg since April 2022, where he leads the Macromolecular Therapeutics Research Group. His research focuses on designing novel polymeric drug delivery systems at the interface between materials chemistry and life science, with particular emphasis on nano-sized vaccines and anti-cancer immunotherapies. Faculty of Chemistry and Pharmacy, Julius Maximilian University Würzburg (2022-present) Emmy-Noether research group leader funded by DFG (2019-2022) Young group leader at Max Planck Institute for Polymer Science (2017-2022) Professor Nuhn's research explores the design of well-defined block copolymers with self-assembling and responsive properties for developing nano-sized carriers that can sense various stimuli including temperature, pH or light. These biodegradable nanocarriers disassemble under physiologically relevant conditions and are engineered for selective immune responses against intracellular pathogens and cancer. His work particularly emphasizes novel strategies to modulate the immune regulatory properties of the tumor microenvironment to combat cancer via next generation nano-immunotherapeutics. Analysis of Professor Nuhn's recent publications reveals a strong focus on pH-responsive nanocarriers, macrophage-targeted therapies, and cancer immunotherapies. His work spans from fundamental polymer chemistry to translational applications, with particular emphasis on liver cancer treatment, macrophage repolarization, and vaccine development. The research demonstrates a consistent trajectory toward increasingly sophisticated nanocarrier systems with multiple responsive elements and targeting capabilities. Liebig fellow of the FCI Emmy-Noether research group leader (DFG) Scholarships from German National Academic Foundation, Max Planck Graduate Center, FCI, AvH, and FWO Professor Nuhn leads the Macromolecular Therapeutics Research Group which develops innovative polymer-based nanocarriers for immunotherapy applications. His research has been supported by multiple grants including the DFG Collaborative Research Center SFB-1066 'Nanodimensional Polymer Therapeutics for Tumor Therapy' where he leads projects focused on treating liver tumors and polymer-induced tumor immunotherapy. The group maintains active collaborations with immunologists, cancer researchers, and clinicians to translate their nanocarrier designs into clinically relevant therapies.

• Hematology
• Oncology
• Immunology
• +3 more

Prof. Vago Luca Aldo Edoardo is an Associate Professor in the Department of Medicine at Vita-Salute San Raffaele University. His research focuses on hematological malignancies, immunotherapy, and stem cell transplantation, with a particular emphasis on blood diseases and viral complications post-transplantation. He teaches hematology courses for medical students and coordinates specialized programs in blood and immune system diseases. Prof. Vago holds editorial roles at BLOOD journal and serves on scientific committees for organizations like the American Society of Hematology (ASH) and Center for International Blood and Marrow Transplant Research (CIBMTR). His work integrates clinical research with translational studies, addressing challenges in leukemia treatment, gene therapy applications, and immune response modulation. Affiliations: Vita-Salute San Raffaele University Roles: Associate Professor, Researcher in Hematology, Editorial Board Member (BLOOD), Scientific Committee Member (ASH, CIBMTR) Research Interests: Leukemia pathogenesis, allogeneic stem cell transplantation, HLA compatibility, immunomodulatory therapies, and viral reactivation in transplant patients. His work often explores the intersection of genetic factors and clinical outcomes in hematological disorders. Advising/Grants: Leads research projects on T-cell engineering and post-transplant immune recovery, collaborating internationally. His grants focus on improving therapeutic strategies for blood cancers and optimizing transplantation protocols.

Nai-Kong CheungView profile

Professor

• Pediatric Oncology
• Immunotherapy
• Antibody Engineering
• +3 more

Nai-Kong Cheung, MD, PhD is the Enid A. Haupt Chair in Pediatric Oncology at Memorial Sloan Kettering Cancer Center (MSKCC), Department of Pediatrics. He leads the Nai-Kong Cheung Lab focused on engineering antibodies and immune cells to treat pediatric solid and liquid tumors. His work integrates antibody-based therapies, CAR-T cell engineering, and pretargeted radioimmunotherapy strategies targeting antigens like GD2, HER2, and GPA33. Education: MD/PhD in Immunology from Harvard Medical School. Key affiliations include the Center for Experimental Therapeutics and Gerstner Sloan Kettering Graduate School. His research addresses challenges in neuroblastoma immunotherapy, including clonal evolution, tumor vasculature targeting, and combination therapies with checkpoint inhibitors. Notable techniques: Development of SADA bispecific antibodies, pretargeted α-particle radiotherapy, and ex vivo T-cell arming strategies. Current projects explore theranostic approaches for colorectal and ovarian cancers, and optimizing antibody responses via β-glucan adjuvants. Labs/Teams: The lab includes researchers specializing in immunology, molecular biology, and translational oncology. Open postdoctoral positions focus on antibody engineering and clinical trial development.

Arielle ElkriefView profile

Associate Clinical Professor

• Oncology
• Immunology
• Microbiology
• +3 more

Arielle Elkrief is a Clinical Associate Professor in the Department of Medicine at the University of Montreal and holds a dual appointment in the Department of Oncology at the Centre hospitalier de l’Université de Montréal (CHUM). She serves as Co-Director of the CHUM Microbiome Centre and is a Research Member of the Montreal Cancer Institute (ICM). Her work bridges clinical oncology and translational research, focusing on the gut and tumor microbiome as biomarkers and therapeutic targets in cancer immunotherapy. Elkrief leads microbiome-centered clinical trials, including fecal microbiota transplantation (FMT), prebiotics, and dietary interventions to enhance immunotherapy efficacy. She has contributed pivotal research on the negative impact of antibiotics on immunotherapy outcomes and developed strategies to mitigate immune-related adverse events like colitis through FMT. Her lab integrates computational biology, microbiology, and oncology to advance precision medicine. Elkrief has published over 75 peer-reviewed articles in journals such as Nature Medicine, Journal of Clinical Oncology, and Clinical Cancer Research. She has received prestigious awards including the American Society of Clinical Oncology Young Investigator Award and the SITC-MRA Women in Melanoma Fellowship. Her research also explores genomic and immune correlates of therapy response in lung and melanoma cancers. She collaborates broadly, including with the Terry Fox Research Institute and the Canadian Cancer Centres Network, to translate microbiome insights into clinical practice.

• Chloroplast biotechnology
• Non-food crops
• Protein secretion
• +5 more

Francesca De Marchis is a Senior Researcher at the Institute of Biosciences and BioResources (IBBR), part of the National Research Council of Italy (CNR), based at the Perugia Division. With over two decades of experience in plant biotechnology research, she has established herself as a leading expert in chloroplast engineering and unconventional protein secretion pathways in plants. Her educational background includes a PhD in "Biology and Ecology" from the University of Perugia (2011-2014) and a Degree in Biological Sciences from the same institution (1992-1997). Dr. De Marchis's research primarily focuses on chloroplast biotechnology , where she has pioneered methods for genetic engineering of tobacco chloroplasts to accumulate proteins of agronomic, pharmaceutical and industrial interest. Her work extends to non-food crops for producing proteins with industrial and pharmaceutical applications, and she has made significant contributions to understanding protein secretion mechanisms in plant cells, particularly unconventional trafficking pathways. Her research has resulted in numerous publications, with an Scopus H-index of 17 and WOS H-index of 16, demonstrating substantial impact in her field. Analysis of her recent publications reveals a strong emphasis on plant-based biopolymer production, chloroplast transformation techniques, and the application of plant systems for pharmaceutical protein production. Her work bridges fundamental molecular biology with practical applications in sustainable materials and therapeutics. Throughout her career, Dr. De Marchis has progressed from research fellow positions to her current role as Senior Researcher, maintaining continuous employment at IBBR-CNR since 2000. Her research has been consistently funded through institutional support from CNR, enabling sustained investigation into plant biotechnology applications. She collaborates extensively within the IBBR network and with researchers across multiple institutions, focusing particularly on chloroplast engineering applications for biopolymer production and protein secretion mechanisms in plant cells.